+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
G

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.

Age: 18Years +All GendersPhase 3
415 locations
B

Actively Recruiting

Central sleep apnea CSA involves periods during sleep when breathing temporarily stops or decreases due to a lack of effort to breathe. This condition can cause excessive daytime sleepiness and poor sleep quality and is linked to higher mortality in patients with heart failure. Researchers are studying the factors that influence treatment choices and how well patients follow these treatments for CSA in Belgium, as well as the effects of these treatments. Participants in this study will receive routine care as part of a registry, without additional interventions from the study. Eligible participants have a confirmed diagnosis of CSA based on specific breathing event measurements from sleep studies. This observational study will follow patients over five years to monitor their treatment decisions, compliance with treatments, and health outcomes. Throughout the study, participants treatment choices and compliance will be tracked along with assessments of their health-related quality of life and sleep quality using surveys like the Short Form 36 Health Survey and Pittsburgh Sleep Quality Index. Researchers will also monitor mortality over the five-year period. The study involves regular evaluations but no experimental treatments, focusing on real-world data collection to better understand CSA management.

Age: 18Years +All Genders
14 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the Suicidal Crisis Intervention SCI as a new short-term treatment method for people after a suicidal crisis or suicide attempt. This study aims to determine if SCI can reduce suicidality and also explore its effect on related factors such as hopelessness, defeat, entrapment, and interpersonal needs. The SCI was developed to provide evidence-based care in Flanders, addressing the limited interventions currently available for this high-risk group. The study compares two groups one receiving the SCI alongside their usual treatment, and the other receiving only their usual treatment. The SCI includes four sessions focusing on providing insight into suicidal crises, involving loved ones, creating a safety plan, and ensuring continuity of care. It emphasizes a structured, person-centered approach and aims to motivate participants toward specialized care. Participants will be followed for approximately 222 days after randomization. Researchers will assess changes in suicidality using the Beck Scale for Suicide Ideation at multiple points, along with secondary measures such as suicidal behavior, hopelessness, defeat, entrapment, isolation, follow-up care readiness, and treatment satisfaction. Assessments are conducted at baseline, 42 days, 132 days, and 222 days to monitor progress and outcomes throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
12 locations
E

Actively Recruiting

Researchers are evaluating whether catheter-based endovascular left atrial appendage occlusion can reduce the risk of ischemic stroke or systemic embolism in people with atrial fibrillation who remain at high stroke risk despite ongoing oral anticoagulation treatment. This multicenter, open-label, randomized controlled trial with blinded assessment aims to clarify the benefit of this intervention for stroke prevention in this population. Participants are randomly assigned to receive either the WATCHMAN device for left atrial appendage occlusion or standard medical care without this procedure. The WATCHMAN device is placed via a catheter to close off the left atrial appendage. Participants continue their oral anticoagulation as prescribed. The study expects an average follow-up of about 4 years, with the primary analysis conducted after 265 stroke or embolism events have occurred. During the study, participants undergo regular monitoring and assessments to track the occurrence of ischemic stroke, systemic embolism, and other cardiovascular events. Cognitive function is also evaluated using the Montreal Cognitive Assessment. Safety and mortality outcomes will be recorded throughout the trial duration. Participants are followed for the full study period estimated at around 4 years to gather comprehensive data on the interventions effects.

Age: 18Years +All GendersPhase Not Applicable
150 locations
Z

Actively Recruiting

Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.

Age: 18Years +All GendersPhase 3
1190 locations